Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy By Ogkologos - June 16, 2025 42 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DeLLphi-304 study Source RELATED ARTICLESMORE FROM AUTHOR Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer EMA Recommends Extension of Indications for Cabozantinib MOST POPULAR NHS staff shortages: What’s needed to build a sustainable cancer workforce? October 12, 2020 How erectile dysfunction drugs could be the key to overcoming treatment... June 21, 2022 New treatment for Waldenstrom’s macroglobulinaemia in England October 1, 2022 Veteran Dresses As Captain America & Brings Joy To Children In... December 20, 2021 Load more HOT NEWS Wishes for a New Year! LGBTQ+ Voices: Listening to Sexual and Gender Minority People Affected by... Predictive Performance of DNA Methylation-based Test in Combination with HPV16/18 Genotyping... Rucaparib Approved as Maintenance Treatment for Some Recurrent Ovarian Cancers
